Traws Current Deferred Revenue from 2010 to 2024
| TRAW Stock | 5.02 0.31 5.82% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 203.4 K | Current Value 180.8 K | Quarterly Volatility 12.7 K |
Check Traws Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Traws Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 15.6 K or Total Revenue of 193.2 K, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 30.16. Traws financial statements analysis is a perfect complement when working with Traws Pharma Valuation or Volatility modules.
Traws | Current Deferred Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.